Palantir a high-risk investment with ’a one-of-a-kind growth and margin model’
QUEBEC - Hôtel-Dieu de Sherbrooke has implemented Steriwave nasal photodisinfection as standard care for orthopedic surgeries, becoming the second Quebec hospital to adopt this infection prevention technology, according to a press release from Ondine Biomedical Inc. (AIM:OBI).
The adoption follows implementation at Hôpital Fleurimont, which reported a 78.8% reduction in surgical site infections among high-risk neuro and spine surgery patients receiving pre-operative Steriwave therapy. These results were presented at the Canadian Spine Society’s annual conference in February 2025.
Steriwave, a non-antibiotic antimicrobial therapy, targets pathogens in the nasal cavity by applying a photosensitive agent followed by illumination with red light. The procedure takes minutes to complete and eliminates bacteria, viruses, and fungi, including drug-resistant organisms.
Surgical site infections remain a significant healthcare challenge, with approximately 69% caused by pathogens colonizing nasal passages. This technology addresses growing concerns about antimicrobial resistance and patient compliance issues associated with traditional topical antibiotics.
The technology has regulatory approvals in Canada, Europe, Australia, and Mexico. In the United States, it has received Qualified Infectious Disease Product designation and Fast Track status from the FDA, with clinical trials underway.
Steriwave is now used in six of Canada’s ten largest hospitals. A UK hospital previously reported a 71% reduction in joint surgery infections after implementing the technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.